



The Decade of Progress in Lung Cancer: From Early Detection over Biomarker-Driven Diagnostics to Personalized Treatment Concepts

Guest Editors:

Prof. Dr. Joanna

Chorostowska-Wynimko

Department of Genetics and
Clinical Immunology, National
Institute of Tuberculosis and
Lung Diseases, 26 Plocka str, 01-
138 Warsaw, Poland

Dr. Torsten Gerriet Blum

Department of General Surgery
and Medical-Surgical Specialties,
University of Catania, Via S. Sofia
78, 95123 Catania, Italy

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editors

Worldwide, lung cancer is the second most common cancer and by far the leading cause of cancer-related death. Yet, over the last decade, substantial progress throughout the lung cancer continuum has led to improved outcomes and patient experiences. This Special Issue focuses on these multifaceted advances in diagnostics and therapeutics for lung cancer patients. While the implementation of population-based low-dose CT screening programmes will result in the long-awaited shift towards curable stages, modern diagnostic and therapeutic concepts integrate personalized approaches as well the latest therapeutics and technology into a multidisciplinary environment. We cordially invite the submission of research articles that will improve our knowledge of these topics. This commemorative Special Issue will publish original research and review articles.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)